Press Releases May 21, 2026 04:17 PM

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies announces participation in major investor conferences and live webcast presentations.

By Maya Rios ADPT

Adaptive Biotechnologies Corporation, a biotechnology company specializing in immune system-based diagnostics and treatments, announced its participation in two upcoming investor conferences — the Craig-Hallum 23rd Annual Institutional Investor Conference and the William Blair 46th Annual Growth Stock Conference. The company will host meetings and present live webcasts showcasing its proprietary immune medicine platform focused on diagnosing and treating diseases such as cancer and autoimmune disorders.

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
ADPT

Key Points

  • Company to participate in two major investor conferences in late May and early June 2026, featuring presentations and meetings with investors.
  • Focus on leveraging adaptive immune system genetics for clinical diagnostics and therapeutics, with products targeting cancer and autoimmune diseases.
  • Provides live and archived webcast access to presentation, enhancing investor transparency and engagement.

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

  • Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MN
    Hosting 1x1 meetings on Thursday, May 28th
  • William Blair 46th Annual Growth Stock Conference – Chicago, IL
    Presentation on Wednesday, June 3rd at 3:20 p.m. Central Time

Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
[email protected]

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
[email protected]


Risks

  • Dependence on continued success and market adoption of their immune medicine platform technology.
  • Uncertainties surrounding clinical product pipeline development timelines and regulatory approvals.
  • Market reception and investor interest in biotechnology sector innovations can be volatile, affecting stock performance.

More from Press Releases

Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026 DLH Announces Filing of New Shelf Registration Statement Jun 4, 2026 FutureCorp Space Acquisition 1 Announces Pricing of $200,000,000 Initial Public Offering Jun 4, 2026